Impact

Empowering Insights: IIWB Director Attended MIT Forum Illuminating Family's Role in Shaping Women's Cognitive Landscape

Retrieved on: 
Friday, March 1, 2024
Other Health, Men, Family, Consumer, Mental Health, Technology, Other Education, University, Education, Women, Other Technology, Health, Well, Museum, CPA, Woman, Multimedia, Journalism, Intelligence, Courage, Matsutarō Shōriki, Management, MIT, Museum of Fine Arts, Art, Diplomatic mission, Impact, Social science, Toy

Ms. Eva Ye highlighted the journey of self-discovery and transformation that women embark on, overcoming familial constraints through innovation and showing the courage to adapt to change.

Key Points: 
  • Ms. Eva Ye highlighted the journey of self-discovery and transformation that women embark on, overcoming familial constraints through innovation and showing the courage to adapt to change.
  • Ms. Grace SHI encouraged stepping beyond traditional boundaries to chart new cognitive territories, underlining the importance of personal evolution and the positive ripple effects it has on society.
  • This MIT dialogue emphasized the intricate ways family shapes women's intellect and spirit, highlighting the importance of a nurturing environment, generational wisdom, and role models.
  • It revealed a journey of transformation, where overcoming familial limitations is seen as a path to personal and societal progress.

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Anxiety, Division, AAAAI, University of Toronto, Hospital, Return, Annual general meeting, Safety, Howard University Hospital, University, HAE, Quality of life, Hereditary angioedema, Patient, University of California, LTP, KALV, Impact, American Academy, Campbelltown Hospital

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting that took place in Washington, DC.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting that took place in Washington, DC.
  • The following presentations occurred at AAAAI 2024:
    Characteristics of Hereditary Angioedema Attacks Among Long-Term Prophylaxis Users: Bob Geng, Allergy and Immunology, University of California, San Diego, California, United States (Poster Presentation)
    Among HAE patients who had treated a recent attack, the location and duration of the most recent attacks were similar between long-term prophylaxis (LTP) and on-demand only users
    Earlier on-demand treatment was associated with a shorter attack duration, regardless of LTP use
    Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers: Sandra Christiansen, University of California San Diego, La Jolla, CA, United States (Poster Presentation)
    The most common barriers to earlier treatment were uncertainty if attack was real, thinking the attack would be mild, and wanting to save treatment for a severe attack
    Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks: James Wedner, Washington University School of Medicine, St Louis, MO, United States (Poster Presentation)
    Both adults and adolescents with HAE reported moderate to extreme anxiety when anticipating use of parenteral on-demand treatment, irrespective of use of on-demand only or on-demand plus LTP
    The results of this study highlighted the association between delayed treatment and treatment-related anxiety, with a higher proportion of patients who delayed treatment experiencing moderate to extreme anxiety
    Anxiety Associated with Refilling On-demand Therapy for HAE Attacks Contributes to Treatment Delay and Non-Treatment: Autumn Burnette, Division of Allergy and Immunology, Howard University Hospital, Washington, DC, United States (Poster Presentation)
    Anxiety associated with not being able to refill on-demand treatment quickly impacted treatment decisions, which contributed to treatment delay or resulted in non-treatment of HAE attacks
    Characterizing the Negative Impact of Delayed On-Demand Treatment of HAE Attacks: Princess Ogbogu, Division of Pediatric Allergy, Immunology, and Rheumatology, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States (Poster Presentation)
    The Impact of On-demand Treatment on Quality of Life of People with HAE: Paula Busse, Department of Medicine, Division of Clinical Immunology, Mount Sinai, New York, United States (Poster Presentation)
    Characterizing the Perspective of Patients With HAE on Prophylactic Treatment: Stephen Betschel, Division of Allergy and Immunology, Department of Medicine, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada (Poster Presentation)
    Only 35% of LTP patients always carried on-demand treatment when away from home, while 43% of prophylaxis patients cited avoiding potential triggers as a reason for not carrying on-demand treatment at all times
    Treatment Patterns of Patients Requiring Redosing of an On-demand Treatment After the Return of an HAE Attack: Constance Katelaris, Department of Medicine, Campbelltown Hospital and Western Sydney University, Sydney, NSW, Australia (Poster Presentation)
    “The results of these surveys clearly conveyed the challenges faced by patients trying to manage their HAE attacks with injectable on-demand treatments.
  • The resulting non-compliance with treatment guidelines may lead to poor clinical outcomes, even among patients receiving LTP,” said Andrew Crockett, Chief Executive Officer of KalVista.
  • “We believe the efficacy and safety data from our phase 3 trial for sebetralstat show a potential path forward to address these persisting unmet needs.”

50K Coalition Founders Call for Increased Diversity Amid DEI Rollbacks

Retrieved on: 
Monday, February 19, 2024
Technology, Training, Communications, Other Science, Courts, Teens, Generation Z, Public Policy, Government, University, Primary, Secondary, Education, Women, Professional Services, DEI (Diversity, Equity and Inclusion), Men, Family, Science, Other Technology, Consumer, Engineering, Social Services, Social Activism, Manufacturing, African Americans, Woman, Coalition, DEI, Climate, SHPE, STEM, Quality of life, Culture, EST, Society, American Indians, Alaska Natives, Organization, National Society, Impact, SWE, Supreme court, NSBE, Student, Nursing

The 50K Coalition will discuss the report’s finding via a virtual symposium – “Engineering a Brighter Future” – on Monday, Feb. 19 at 12:00 p.m. EST.

Key Points: 
  • The 50K Coalition will discuss the report’s finding via a virtual symposium – “Engineering a Brighter Future” – on Monday, Feb. 19 at 12:00 p.m. EST.
  • The report comes amid the current rollback of diversity, equity, and inclusion (DEI) efforts in academic and corporate environments.
  • The group includes more than 60 diversity engineering organizations, academic institutions, and corporations committed to increasing diverse representation in engineering.
  • While the 50,000 graduates milestone was achieved earlier than the target date, the Coalition acknowledges there is much more to be done.

EllisDon Publishes 2023 Impact Report Addressing Vital Environmental, Social, and Governance Matters

Retrieved on: 
Tuesday, March 5, 2024
EllisDon, Attention, Impact, Annual report

MISSISSAUGA, ON, March 5, 2024 /CNW/ - Today, EllisDon published the second edition of their annual Impact Report.

Key Points: 
  • MISSISSAUGA, ON, March 5, 2024 /CNW/ - Today, EllisDon published the second edition of their annual Impact Report.
  • The Impact Report is a comprehensive annual report that highlights EllisDon's mission to address important environmental, social and governance issues that not only impact the company but all of the communities in which we work.
  • "Sustainability, inclusivity, and innovation are key pillars of everything we do at EllisDon — from our corporate culture to our approach to business," said Jody Becker, Chief Operating Officer & Executive Vice President, Infrastructure Services & Technology.
  • The Impact Report identifies key areas of focus across the company where proactive steps and achievements have been made, as well as where more attention is needed, and outlines a roadmap with actionable steps to meet its objectives.

Impact Crew Teams Up with Warner Bros. Discovery and Netflix to Modernize Production Hiring

Retrieved on: 
Tuesday, February 27, 2024
Crew, Life, MAAC, MEAA, Impact, Warner Bros. Discovery, Partnership, Music

Discovery and Netflix aimed at improving the way productions source and hire crew talent.

Key Points: 
  • Discovery and Netflix aimed at improving the way productions source and hire crew talent.
  • These include ARRAY Crew, The Handy Foundation, ReelWorks, The London Screen Academy, NOVAC, MediaMKRS, MEAA, MAAC, and the EICOP.
  • Discovery and Netflix productions to build new custom features and reporting tools, specifically tailored to meet each studio's hiring and talent management needs.
  • AvailCheck has been used to source crew for over 100 productions, engaging over 4,700 qualified crew with job opportunities.

New Survey Reveals that Almost 80 per cent of Women Face Ageism in the Workplace

Retrieved on: 
Monday, February 26, 2024
Bias, Newsletter, Woman, Workplace, DEI, Education, Complex, Culture, Racism, Prejudice, Intersectionality, Observation, Organizational culture, HR, Organization, Policy, Knowledge, Stereotype, Male, Impact, Comment, Nursing

The survey explores the nuances of ageism and its impact on women in the workplace.

Key Points: 
  • The survey explores the nuances of ageism and its impact on women in the workplace.
  • More than 80 per cent (80.7 per cent) have witnessed women in the workplace being treated differently because of their age.
  • Survey participants expressed the belief that age is often inappropriately correlated with perceived performance and success, a bias that disproportionately affects women.
  • The survey, Exploring the Impact of Ageism on Women in the Workplace, demonstrates that age-based discrimination is an issue impacting women in the workplace across countries, organizations, industries, and sectors.

Reducing Waste and Managing Commitments Top Key Priorities for FinOps Practitioners

Retrieved on: 
Thursday, February 22, 2024
Artificial intelligence, AI, Forecasting, Education, Growth, Economy, Linux Foundation, Organization, Automation, Economics, Machine learning, Impact, Research

SAN FRANCISCO, Feb. 22, 2024 /PRNewswire/ -- The FinOps Foundation, a part of The Linux Foundation's non-profit technology consortium focused on advancing the people and practice of FinOps, today released research showing that reducing wasted cloud spend is the number one priority for FinOps practitioners in the past year. The fourth annual State of FinOps survey also found that 'ensuring executive support and organizational alignment' is seen as what is most needed to overcome that challenge.

Key Points: 
  • Now, the top priorities are reducing waste, managing commitment discounts, and improving cost forecasting.
  • "This survey will help the Foundation better understand practitioners so we can improve education and other initiatives to help FinOps practitioners get the most value out of the cloud to drive efficient growth."
  • After reducing waste, managing commitment-based discounts was the No.
  • Forecasting returns high on the list of priorities for organizations, signaling a need to achieve predictability in cloud spend.

PreludeDx™ to Present Data in DCIS and Stage I, II Early Breast Cancer at the 2024 Miami Breast Cancer Conference

Retrieved on: 
Thursday, February 22, 2024
Cleveland Clinic, Therapy, DCIS, MD, IBR, MBCC, Conference, Radiation, Medicine, Patient, Impact, Radiation therapy, Woman, Medical imaging

LAGUNA HILLS, Calif., Feb. 22, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that data will be highlighted in three separate poster presentations at the 2024 Miami Breast Cancer Conference (MBCC), held on March 7 – 10, 2024 at the Fontainebleau, Miami Beach, FL.

Key Points: 
  • LAGUNA HILLS, Calif., Feb. 22, 2024 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that data will be highlighted in three separate poster presentations at the 2024 Miami Breast Cancer Conference (MBCC), held on March 7 – 10, 2024 at the Fontainebleau, Miami Beach, FL.
  • "We are excited to share data regarding our novel biosignature for invasive Stage I, II breast cancer test for radiation therapy, as well as clinical utility data on our DCISionRT test for DCIS at the prestigious MBCC conference," said Dan Forche, President and CEO of PreludeDx.
  • "We look forward to connecting with colleagues and sharing our vision for future early-stage breast cancer products, as well as advancing collaboration opportunities."
  • Title: Impact on Radiation Therapy Recommendation and Treatment Modality for Patients with Ductal Carcinoma in Situ Using the 7-Gene Biosignature: Analysis of the PREDICT Study
    Presenter: Chirag S. Shah, MD, Co-Director of Breast Radiation Oncology, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
    Title: Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women with Low-Risk DCIS after Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-year Ipsilateral Breast Recurrence (IBR) Rates
    Presenter: Frank A. Vicini, MD, FASTRO, Radiation Oncologist at Michigan HealthCare Professionals, member of NRG Oncology

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Retrieved on: 
Friday, February 16, 2024
Pharmaceutical, Health, Clinical Trials, AAAAI, Return, Anxiety, Convention center, HAE, Quality of life, Hereditary angioedema, Abstract, KALV, Patient, Q&A, Impact, American Academy, Pharmaceutical industry

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Washington, DC from February 23-26.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Washington, DC from February 23-26.
  • Results shared as an oral poster presentation and Q&A
    Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers (#216): Sandra Christiansen, Maeve O’Connor, Julie Ulloa, Sherry Danese, Vibha Desai, Shawn Czado, Paul Audhya, Paula Busse.
  • Results shared as an oral poster presentation and Q&A
    Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks (#257): James Wedner, Cristine Radojicic, Julie Ulloa, Sherry Danese, Vibha Desai, Shawn Czado, Paul Audhya, Sandra Christiansen.
  • Results shared as an oral poster presentation and Q&A
    Characterizing the Perspective of Patients with HAE on Prophylactic Treatment (#270): Stephen Betschel, Cristine Radojicic, Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, William Lumry.

Nonprofit Organization to Award Funds for the Research of Pulmonary Hypertension

Retrieved on: 
Thursday, February 15, 2024
Pulmonary hypertension, Phenomenon, Team Capinordic, High, University, Team, Diagnosis, Impact, Research, Pharmaceutical industry

WHEATON, IL, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Non-profit organization Team PHenomenal Hope (Team PH) is proud to award research funds for the sixth year in the field of pulmonary hypertension (PH). The organization will reward studies of novel concepts in PH with a potential to transform the field. Letters of intent (LOIs) will be accepted until Friday, March 8.

Key Points: 
  • Team PHenomenal Hope (Team PH) seeks submissions for its PHenomenal Impact Fund for Global PH Research, marking the sixth consecutive year of funding innovative studies in pulmonary hypertension (PH)
    WHEATON, IL, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Non-profit organization Team PHenomenal Hope (Team PH) is proud to award research funds for the sixth year in the field of pulmonary hypertension (PH).
  • The organization will reward studies of novel concepts in PH with a potential to transform the field.
  • This year the award is focused on studies that will help expand access to care and improve clinical status.
  • These topic areas were outlined at the PHenomenal Hope 2023 research symposium in Boston last December.